Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment

Texto completo
Autor(es):
Bueno, C. B. F. ; Trarbach, E. B. ; Bronstein, M. D. ; Glezer, A.
Número total de Autores: 4
Tipo de documento: Artigo Científico
Fonte: Pituitary; v. 20, n. 3, p. 295-300, JUN 2017.
Citações Web of Science: 4
Resumo

Background About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). Objective To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma. Study design and patients Cross-sectional retrospective case-control study analyzing the frequency of five DRD2 polymorphisms in 148 patients with prolactinoma and 349 healthy subjects. The association of genetic variants and clinical characteristics with CAB responsiveness was performed in 118 patients (mean age at diagnosis 29 years; range 11-61 years) with hormonal evaluation. Patients with prolactin (PRL) normalization were considered as responders. Results No association in genotypes and allele proportions was found comparing patients and controls. On pharmacogenetic study, 118 patients on CAB were included and 20% were non-responders. No association was found between clinical characteristics (gender, age, PRL level and tumor size at diagnosis) and polymorphisms of DRD2 with CAB responsiveness. Otherwise, there was association between polymorphisms rs1076560 (allele A) and rs1800497 (allele T) and the presence of macroadenomas. Conclusion No correlation was found between DRD2 polymorphisms and CAB responsiveness in patients with prolactinoma. More data are necessary in order to assess the influence of DRD2 genotyping on DA treatment response. (AU)

Processo FAPESP: 11/19932-5 - Influência de polimorfismos dos genes dos receptores de dopamina D2 e de somatostatina SST2 e SST5 nas manifestações clínicas e na resposta ao tratamento de pacientes portadores de adenomas hipofisários
Beneficiário:Andrea Glezer
Modalidade de apoio: Auxílio à Pesquisa - Regular